Assembly Biosciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jason A. Okazaki
- Full Time Employees
- 73
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Two Tower Place South San Francisco CA United States of America 94080
- IPO Date
- Dec 17, 2010
- CIK
- 0001426800
- Website
- assemblybio.com
- Similar Companies
- Business
- Assembly Biosciences, Inc. (Nasdaq: ASMB) is a clinical-stage biotechnology company focused on developing innovative antiviral therapeutics targeting viral diseases with unmet medical needs, including hepatitis B virus (HBV), norovirus, and other viral infections. The company discovers, develops, and advances small-molecule antiviral agents through preclinical and clinical stages; its pipeline features emvododstat, a next-generation oral, selective, small-molecule inhibitor of diaminopimelate aminotransferase (DAPTAse) in Phase 2 development for HBV; ABI-4334, an optimized core inhibitor candidate advancing toward Phase 1; and earlier-stage programs against norovirus and dengue. Assembly Biosciences operates primarily in the United States, with headquarters in South San Francisco, California, founded in 2010 as a leader in microbiome therapeutics before pivoting to virology in recent years. Recent strategic shifts include the discontinuation of its microbiome gastrointestinal program in 2022 to concentrate resources on virology; in 2024, the company reported positive interim data from the Phase 2a SYNERGY-HBV trial for emvododstat, supporting dose selection and combination potential with nucleos(t)ide analogues; and in October 2024, Assembly Biosciences announced the selection of ABI-4334 as a development candidate following extensive optimization efforts. No major acquisitions, funding rounds, or partnerships were reported in the last 1-2 years, though the company continues to advance its HBV portfolio toward potential registrational studies. Assembly Biosciences targets patients and healthcare providers in the antiviral therapeutics market, with operations centered in the U.S. biopharma hub.
Company News
Analyzing RYTHM (NASDAQ:RYM) and Assembly Biosciences (NASDAQ:ASMB)
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
Best Momentum Stocks to Buy for September 17th
New Strong Buy Stocks for September 17th
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?
Should You Buy Assembly Biosciences (ASMB) After Golden Cross?
5 Stocks With Recent Price Strength Buoyed by a Strong August
Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going
Best Momentum Stocks to Buy for August 25th
New Strong Buy Stocks for August 25th
Best Momentum Stocks to Buy for August 21st
New Strong Buy Stocks for August 21st
Are You Looking for a Top Momentum Pick? Why Assembly Biosciences (ASMB) is a Great Choice
Wall Street Analysts Think Assembly Biosciences (ASMB) Could Surge 40.66%: Read This Before Placing a Bet
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal
Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates